Hologic, Inc. (NASDAQ:HOLX) Shares Acquired by Lecap Asset Management Ltd.

Lecap Asset Management Ltd. lifted its position in Hologic, Inc. (NASDAQ:HOLX) by 733.8% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 50,461 shares of the medical equipment provider’s stock after buying an additional 44,409 shares during the quarter. Hologic accounts for about 1.0% of Lecap Asset Management Ltd.’s investment portfolio, making the stock its 5th biggest holding. Lecap Asset Management Ltd.’s holdings in Hologic were worth $3,638,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in HOLX. Sanctuary Advisors LLC acquired a new stake in shares of Hologic in the 2nd quarter valued at $1,212,000. Czech National Bank raised its holdings in Hologic by 6.4% during the third quarter. Czech National Bank now owns 47,316 shares of the medical equipment provider’s stock valued at $3,854,000 after buying an additional 2,843 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Hologic by 17.9% in the third quarter. GAMMA Investing LLC now owns 3,832 shares of the medical equipment provider’s stock worth $312,000 after buying an additional 582 shares during the last quarter. Marcum Wealth LLC bought a new stake in shares of Hologic during the 3rd quarter worth about $202,000. Finally, Wedmont Private Capital boosted its stake in shares of Hologic by 3.7% during the 3rd quarter. Wedmont Private Capital now owns 4,519 shares of the medical equipment provider’s stock worth $361,000 after acquiring an additional 162 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Trading Down 10.1 %

HOLX stock opened at $65.45 on Friday. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. The firm has a market cap of $14.77 billion, a P/E ratio of 19.65, a P/E/G ratio of 2.35 and a beta of 0.98. Hologic, Inc. has a 1-year low of $64.87 and a 1-year high of $84.67. The business’s 50 day moving average is $72.63 and its 200-day moving average is $77.86.

Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. Equities analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the business’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the transaction, the chief operating officer now directly owns 27,957 shares of the company’s stock, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 1.88% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

HOLX has been the subject of several analyst reports. Royal Bank of Canada reduced their target price on Hologic from $88.00 to $85.00 and set a “sector perform” rating for the company in a report on Thursday. Needham & Company LLC lowered Hologic from a “buy” rating to a “hold” rating and set a $90.00 price objective on the stock. in a research note on Monday. StockNews.com upgraded Hologic from a “hold” rating to a “buy” rating in a research note on Thursday, November 14th. Jefferies Financial Group assumed coverage on Hologic in a report on Tuesday, December 10th. They issued a “hold” rating and a $85.00 target price on the stock. Finally, Stephens reiterated an “overweight” rating and set a $84.00 price target on shares of Hologic in a report on Thursday. Ten research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $85.77.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.